Clinical Trials Browser

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 4 Not yet recruiting

31 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04005716 2025-02-28

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3 Completed

457 enrolled 20 charts

Thoracic

Small Cell Lung Carcinoma

NCT06375109 2024-04-19

NeoSCLC-001

Phase 2 Not yet recruiting

60 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Phase 2 Unknown

21 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05582031 2023-06-07

REFIT-MSS

Phase 2 Withdrawn

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04542369 2023-05-03

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Phase 2 Unknown

15 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase 2 Unknown

25 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

ACROPOLI

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NeoSCLC-001

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

REFIT-MSS

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy